CeriBell (NASDAQ:CBLL) Director Rebecca Robertson Sells 827 Shares

CeriBell, Inc. (NASDAQ:CBLL) Director Rebecca Robertson sold 827 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.80, for a total transaction of $14,720.60. Following the completion of the transaction, the director owned 18,749 shares of the company’s stock, valued at approximately $333,732.20. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

CeriBell Stock Down 1.1%

Shares of NASDAQ CBLL traded down $0.19 during mid-day trading on Friday, hitting $17.70. The company had a trading volume of 172,453 shares, compared to its average volume of 347,316. The company has a market capitalization of $666.23 million, a PE ratio of -12.04 and a beta of 1.12. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.73 and a quick ratio of 9.35. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $24.33. The business’s 50-day simple moving average is $20.84 and its 200 day simple moving average is $16.42.

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. The firm had revenue of $24.78 million during the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%. On average, analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

CBLL has been the topic of a number of analyst reports. TD Cowen restated a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. Canaccord Genuity Group raised their price target on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.67.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after buying an additional 1,162,200 shares during the last quarter. KCM Capital Inc purchased a new position in shares of CeriBell during the fourth quarter worth approximately $21,930,000. Royce & Associates LP acquired a new position in shares of CeriBell in the 4th quarter valued at $11,695,000. Adage Capital Partners GP L.L.C. purchased a new stake in CeriBell in the 4th quarter valued at $10,965,000. Finally, CenterBook Partners LP boosted its stake in CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after purchasing an additional 389,584 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.